Sotagliflozin indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy
Dental and Pharmaceutical Benefits Agency (TLV)
Record ID 32018001141
English
Authors' objectives:
This is the assessment of the relative effectiveness of ‘Sotagliflozin indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy.’
Details
Project Status:
Completed
Year Published:
2019
URL for published report:
https://eunethta.eu/ptja04-sotagliflozin-indicated-as-an-adjunct-to-insulin-therapy-to-improve-glycaemic-control-in-adults-with-type-1-diabetes-mellitus-with-a-body-mass-index-bmi-%E2%89%A5-27-kg/
Requestor:
HTA agencies
English language abstract:
An English language summary is available
Publication Type:
Rapid Review
MeSH Terms
- Diabetes Mellitus, Type 1
- Hypoglycemic Agents
- Adult
- Sodium-Glucose Transporter 2 Inhibitors
Contact
Organisation Name:
European Network for Health Technology Assessment
Contact Email:
eunethta@zinl.nl
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.